Sun Pharma Launches Breakthrough Psoriasis Drug Ilumya in India

Sun Pharmaceutical Industries has introduced its blockbuster biologic therapy Ilumya (Tildrakizumab) in India, marking a major step toward expanding access to advanced treatments for moderate-to-severe plaque psoriasis. Known for selectively targeting IL-23, Ilumya has already made its mark across 35 global markets, including the United States, and is now set to benefit patients in Sun Pharma’s home country.

The launch comes as Sun Pharma’s specialty medicines business continues to show strong momentum, recording $333 million in sales in Q2FY26, a 16.4% year-on-year increase. Ilumya has been a key driver of this growth internationally, thanks to its ability to deliver long-lasting and significant skin clearance. Sun Pharma has been progressively introducing more of its global specialty products to India, including Cequa for dry-eye disease.

Ilumya’s entry into the Indian market follows promising results from a Phase-3 clinical study conducted on 115 Indian patients. The trial showed exceptional outcomes, with 93.9% achieving PASI 75 and 78.1% achieving PASI 90 by week 28, demonstrating high levels of skin improvement. Dermatology experts involved in the study highlighted the drug’s strong safety profile and its potential to transform psoriasis care by offering an effective, durable, and well-tolerated treatment option.